重组质粒-肝细胞生长因子注射液适用于治疗严重下肢缺血性疾病导致的肢体静息痛。此次撤回药品注 册申请后，光谷人福将尽快完善研究资料并重新申报药品注册。此次撤回申请并非终止该项目。 人民财讯12月2日电，人福医药（600079）12月2日公告，公司控股子公司光谷人福(公司持有其81.3%的 股权)近日收到国家药监局签发的《药品注册申请终止通知书》，同意光谷人福撤回重组质粒-肝细胞生 长因子注射液的注册申请。 ...

证券代码：600079 证券简称：人福医药 编号：临 2025-125 人福医药集团股份公司 关于子公司撤回药品注册申请的公告 光谷人福于2024年12月向国家药品监督管理局递交该药品的上市注册申请并予以 受理。截至目前，pUDK-HGF研发项目的累计研发投入约为1.6亿元。此外，公司于2021 年收购光谷人福20.33%股权，将其纳入合并报表范围，收购日pUDK-HGF研发项目可辨 认资产的分摊金额为2.38亿元。根据该项目最新审评情况，经审慎研究，公司决定主动 撤回本次申请。本次注册申请撤回后，公司将根据监管要求和技术要求，对研究资料进 行充分评估完善后重新申报。本次撤回申请并非终止本项目。 三、对公司的影响及风险提示 一、药品信息 药品名称：重组质粒-肝细胞生长因子注射液 剂型：注射剂 申请事项：境内生产药品注册上市许可 注册分类：治疗用生物制品1类 申请人：光谷人福 审查结论：同意本品注册申请的撤回，终止注册程序。 二、药品研究的其他相关情况 重组质粒-肝细胞生长因子注射液（以下简称"pUDK-HGF"）适用于治疗严重下 肢缺血性疾病导致的肢体静息痛。pUDK-HGF为治疗用生物制品1类新药，目前国内 ...

Core Viewpoint - The company announced the withdrawal of its drug registration application for a new biological product aimed at treating severe lower limb ischemic diseases, indicating a proactive approach to meet regulatory and technical requirements [1] Group 1: Company Actions - The company’s subsidiary, Guanggu Renfu, received a termination notice from the National Medical Products Administration regarding its application for the recombinant plasmid-hepatocyte growth factor injection [1] - The company has decided to voluntarily withdraw the application and will improve research materials before reapplying [1] Group 2: Financial and Development Insights - The cumulative research investment for the drug development has reached approximately 160 million yuan [1] - The company expects that this withdrawal will not have a significant impact on its current financial performance [1] Group 3: Industry Context - The development cycle for pharmaceutical products is long and involves multiple stages, which introduces uncertainties [1] - The company commits to timely information disclosure in accordance with regulatory requirements [1]

Core Viewpoint - The company announced that its subsidiary, Wuhan Guanggu Renfu Biopharmaceutical Co., Ltd., has received a termination notice from the National Medical Products Administration regarding the withdrawal of its drug registration application for the recombinant plasmid-hepatocyte growth factor injection [1] Group 1 - The subsidiary has officially withdrawn its application for the recombinant plasmid-hepatocyte growth factor injection [1]

Group 1 - Contemporary Group has been placed under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure and illegal financing [1][2] - The company was founded in July 1988 and is registered in Wuhan with a registered capital of 5.5 billion yuan, expanding into various sectors including pharmaceuticals, consumer goods, and culture [2] - The company has faced multiple bond defaults since April 2022, leading to a restructuring application filed by creditors in September 2024 due to its inability to repay debts [2] Group 2 - The former CSRC official, Guo Xudong, who was involved in the regulatory process, has been implicated in serious misconduct and later joined Contemporary Group as vice chairman [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 【导读】涉嫌信披违法违规、违规融资等，当代集团被立案 中国基金报记者 晨曦 当代集团，被立案！ 当代集团称，在立案调查期间，公司将积极配合中国证监会的调查工作，同时严格按照监管要求及相关规则，及时履行后续进展情况的信息披露义务。 公开信息显示，当代集团成立于1988年7月，是注册在武汉东湖新技术开发区内的一家民营高新技术集团公司，注册资本为55亿元；集团创始人为艾路 明。发展三十多年，"当代系"逐渐拓展至医药、消费、文化等各产业领域，曾控股人福医药、三特索道等多家上市公司。 2022年4月，当代集团首只债券发生违约事件，随后多只债券陆续发生违约。2023年8月，人福医药、三特索道等公司公告称，艾路明因涉嫌信息披露违法 违规被中国证监会立案。 12月2日，武汉当代科技产业集团股份有限公司发布公告称，其于11月28日收到中国证监会《立案告知书》。因涉嫌信息披露违法违规、违规融资等，中 国证监会决定对其立案。 2024年9月，债权人以当代集团不能清偿到期债务且明显缺乏清偿能力，向武汉中院提交重整申请。 此外，由于未在法定期限内披露定期报告，当代集团及艾路明在2025 ...

【导读】涉嫌信披违法违规、违规融资等，当代集团被立案 中国基金报记者 晨曦 当代集团，被立案！ 12月2日，武汉当代科技产业集团股份有限公司发布公告称，其于11月28日收到中国证监会《立案告知书》。因涉嫌信息披露违法违规、 违规融资等，中国证监会决定对其立案。 公开信息显示，当代集团成立于1988年7月，是注册在武汉东湖新技术开发区内的一家民营高新技术集团公司，注册资本为55亿元；集团 创始人为艾路明。发展三十多年，"当代系"逐渐拓展至医药、消费、文化等各产业领域，曾控股人福医药、三特索道等多家上市公司。 2022年4月，当代集团首只债券发生违约事件，随后多只债券陆续发生违约。2023年8月，人福医药、三特索道等公司公告称，艾路明因 涉嫌信息披露违法违规被中国证监会立案。 2024年9月，债权人以当代集团不能清偿到期债务且明显缺乏清偿能力，向武汉中院提交重整申请。 此外，由于未在法定期限内披露定期报告，当代集团及艾路明在2025年曾多次被上交所予以通报批评、公开谴责等纪律处分。 2025年4月，武汉中院裁定批准重整计划，当代集团进入重整计划执行阶段。2025年6月，当代集团股东变更为国通信托（代表相关信托 计 ...

Core Insights - The flu positive rate in China has reached nearly 45%, indicating a significant rise in flu cases, with some provinces experiencing high epidemic levels [1] - Investors are closely monitoring the supply and sales of flu medications and vaccines from listed pharmaceutical companies, which are actively preparing to meet public health needs [1] Group 1: Drug and Vaccine Supply - Multiple listed companies have reported sufficient reserves of flu medications and vaccines, ensuring stable supply capabilities [2] - Renhe Pharmaceutical has initiated a priority supply mechanism for Oseltamivir, while Dajia Weikang has adjusted production capacity based on market demand [2] - The entire supply chain, including raw material suppliers like Rhine Bio, is collaborating to ensure a robust response to market needs [2] Group 2: Vaccine Development - Companies are focusing on flu vaccines as a key area for development, with several achieving significant progress by 2025 [3] - Zhejiang Tianyuan Biopharmaceutical's quadrivalent flu vaccine "Yufening" has been approved for sale, alongside its trivalent vaccine "Yuganning" [3] - Baike Bio has innovated with a freeze-dried nasal spray flu vaccine, which has been upgraded to a liquid form for easier administration [3] Group 3: Treatment Options - Companies are building a diverse matrix of flu medications to address various symptoms and treatment needs [5] - Zhongsheng Pharmaceutical is advancing the commercialization of Anladiwei tablets for treating uncomplicated influenza, while Jichuan Pharmaceutical is developing a novel flu treatment [5] - Oseltamivir remains a commonly used antiviral, with multiple companies like Renfu Pharmaceutical and Dajia Weikang actively involved in its production [5][6] Group 4: Symptomatic Relief - Several companies are providing symptomatic treatments for flu, including Lisheng Pharmaceutical's Acetaminophen and various products from Zhenbaodao for symptom relief [6] - Companies like Foci Pharmaceutical produce a range of cold and flu medications, ensuring comprehensive treatment options for patients [6]

Core Insights - Wuhan is positioned as a key strategic hub in China's development, with a focus on high-quality growth and innovation in technology and industry [4][10][11] - The establishment of the Jiufengshan Laboratory aims to create a global center for advanced compound semiconductor research, reflecting the city's commitment to technological self-reliance and innovation [2][7][9] - The integration of industry, academia, and research is emphasized as a critical factor for Wuhan's technological breakthroughs and economic development [8][9] Group 1: Strategic Development - Wuhan is tasked with significant responsibilities in the national development strategy, aiming to be a leading force in the central region's rise [6][10] - The city is focusing on high-quality development practices during the 14th Five-Year Plan and is preparing for the 15th Five-Year Plan [4][6] - The economic output of the Wuhan metropolitan area is projected to exceed 3.6 trillion yuan in 2024, accounting for 29% of the Yangtze River middle reaches urban agglomeration [11] Group 2: Technological Innovation - The Jiufengshan Laboratory operates over 300 projects and has implemented a 24-hour work schedule to enhance delivery efficiency [7] - Wuhan's high-tech enterprises are expected to surpass 15,000, with technology contract transaction volumes exceeding 300 billion yuan by 2024 [11] - The city is recognized for its strong educational foundation, housing over 90 universities and 1.4 million students, contributing to its innovation capabilities [18] Group 3: Urban Development and Governance - Wuhan is implementing a community governance model that emphasizes proactive service delivery to residents, enhancing safety and community engagement [12][13] - The city is undergoing urban renewal projects that blend historical preservation with modern functionality, aiming for high-quality living standards [23][24] - The establishment of a digital public infrastructure platform is transforming urban governance and service delivery [12][13] Group 4: Logistics and Economic Integration - Wuhan has become a key logistics hub, facilitating direct shipping routes to Europe and reducing logistics costs by approximately 15% [19] - The city is enhancing its role in the national logistics network, with the establishment of multiple logistics hubs and international transport routes [19] - The integration of regional economies is being prioritized, with collaborative efforts to strengthen the Wuhan metropolitan area and its surrounding cities [11][19]

Core Viewpoint - Wuhan is positioned as a key strategic hub in China's development, with a focus on high-quality growth and innovation, particularly in the context of the "14th Five-Year Plan" and the upcoming "15th Five-Year Plan" [2][4][10]. Group 1: Strategic Importance - Wuhan is entrusted with significant responsibilities in the national development framework, emphasizing its role in implementing major national strategies [4][6]. - The city aims to integrate its development with national needs, showcasing its capabilities in technology and innovation [7][10]. Group 2: Technological Innovation - Wuhan's Nine Peaks Mountain Laboratory is a key facility focusing on compound semiconductor research, operating 24/7 to meet national demands [4][5]. - The number of high-tech enterprises in Wuhan is projected to exceed 15,000 by 2024, with technology contract transaction volume surpassing 300 billion yuan [5][6]. Group 3: Regional Development - The Wuhan metropolitan area is expected to achieve an economic total of 3.6 trillion yuan in 2024, accounting for 29% of the Yangtze River Middle Reaches urban cluster [6][8]. - Collaborative development with surrounding cities is emphasized, with a focus on enhancing regional industrial layouts [5][6]. Group 4: Urban Governance and Quality of Life - Wuhan is exploring modern governance models, utilizing digital infrastructure to improve community services and emergency response systems [6][8]. - The city is implementing urban renewal projects that balance historical preservation with modern functionality, enhancing overall urban quality [11][12]. Group 5: Logistics and Connectivity - Wuhan has become a crucial logistics hub, with the establishment of the "China-Europe Railway Express" and improved transportation links reducing logistics costs by approximately 15% [9][10]. - The city is enhancing its role in domestic and international logistics, aiming to strengthen its position in the new development landscape [9][10].